NCT07141810尚未招募4 期
Early Antifibrotic Therapy for f-ILD
Shanghai Pulmonary Hospital, Shanghai, China0 个研究点目标入组 104 人开始时间: 2025年10月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 104
- 主要终点
- FVC %predict
研究概览
简要总结
Early antifibrotic therapy for f-ILD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
盲法说明
Masking Description
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1) Able to understand the procedures and methods of this study, willing to strictly follow the clinical trial protocol to complete this study, and sign the informed consent; 2) The age of signing the informed consent is 40-85 years old (including both ends of the value); 3) Weight: male ≥50 kg, female ≥40 kg; 4) During screening, FVC accounted for more than 45% of the estimated value and 90%; 5) The percentage of pulmonary carbon monoxide dispersion (DLCO) to the predicted value (corrected by Hb value) during screening was ≥30% and ≤90%; 6) Diagnosed with fibrotic ILD: In the past 12 months, at least 3 months after basic treatment such as glucocorticoids and immunosuppressants, reexamination of chest CT showed fibrotic features such as diffuse mesh shadow, honeycomb lung, and tractive bronchiectasis in both lungs, and the lesions could not be further absorbed.
排除标准
- •Patients with unstable disease (IPF) assessed by investigators during screening had acute exacerbations during screening or within 3 months before randomization;
- •Patients who are likely to require lung transplantation within 6 months or whose expected survival is less than 1 year as assessed by the investigators at the time of screening;
- •During screening, chest HRCT indicated that the range of emphysema exceeded the range of pulmonary fibrosis (based on independent imaging evaluation results);
- •Patients with airway obstruction disease (such as FEV1/FVC after bronchodilator);
- •Diagnosed with IPF
- •Diagnosis of PPF according to the 2022 ATS/ERS/JRS/ALAT guidelines
- •Patients with other types of respiratory diseases that the investigators assessed might affect the study results;
- •Patients who need to receive oxygen therapy for 15 hours or more per day;
- •Resting pulse oxygen < 90% (sea level to 1500m above sea level) or < 85% (altitude > 1500m) when breathing indoor air during screening;
- •with other poorly controlled underlying conditions (such as NYHA Class III or IV congestive heart failure, acute myocardial infarction, unstable angina, hemorrhagic or ischemic stroke, pulmonary hypertension requiring treatment within the 6 months prior to screening), Patients assessed by the investigator as unsuitable for the study;
- •Patients who had an active tuberculosis infection in the 12 months prior to screening, or had a bacterial, viral, fungal, or microbial infection requiring treatment with any clinical symptoms within the 4 weeks prior to randomization;
- •Patients diagnosed with NCOV infection 1 month before screening and/or during screening (NCOV nucleic acid testing is not part of this study and can be performed on demand);
- •Patients who plan to receive NCOV vaccine and other vaccines from 1 month before screening to 1 month after the last dose;
- •Patients with a history of malignant tumors (except cured basal cell carcinoma of the skin and cervical carcinoma in situ) within 5 years prior to screening, or who are currently being evaluated for potential malignant tumors;
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 upper limit of normal (ULN) or total bilirubin ≥1.5× upper limit of normal (ULN);
- •Serum creatinine ≥1.5× upper limit of normal (ULN);
- •Active hepatitis, syphilis or HIV antibody positive patients;
- •Major surgery (general anesthesia) within 3 months prior to screening, or surgery planned to be performed during the study period that the investigator assessed would affect the study endpoint;
- •Participated in any clinical trial (including other investigational drug/investigational device therapy) within 3 months prior to screening, or was still within 5 half-lives of the investigational drug at the time of screening;
- •Current smoking history, smoking cessation ≤3 months, or unable to abstain from smoking for the entire study period;
- •Suspected or confirmed history of alcohol or drug abuse;
- •Known allergy to the investigational drug and its ingredients;
- •Pregnant and lactating women, female subjects who plan to become pregnant during the study period, or patients who do not wish to use contraceptives that meet the protocol requirements during the trial;
- •Other conditions assessed by the investigator as unsuitable for participation in the study.
研究组 & 干预措施
Antifibrotic drug
Active Comparator
干预措施: Antifibrotic drugs (nidanib or pirfenidone) (Drug)
结局指标
主要结局
FVC %predict
时间窗: 48 weeks
次要结局
未报告次要终点
研究者
Jiuwu Bai
Doctor
Shanghai Pulmonary Hospital, Shanghai, China
相似试验
招募中
不适用
Anti-fibrotic treatment in patients with idiopathic pulmonary fibrosis:A cohort studyidiopathic pulmonary fibrosisJPRN-UMIN000020392niversity of Occupational and Environmental Health, Japan100
进行中（未招募）
不适用
A protocol based treatment for debilitating fibrosing skin disorders with (anti-CD-20), rituximabFibrosing skin disordersEUCTR2009-012034-70-BEniversity Hospital Ghent
Unknown
不适用
It's Not JUST Idiopathic Pulmonary Fibrosis StudyIdiopathic Pulmonary FibrosisInterstitial Lung DiseaseNCT03670576University of Nottingham250
已完成
2 期
Treatment of Idiopathic Pulmonary Fibrosis With ThalidomideIdiopathic Pulmonary Fibrosis (IPF)NCT00162760Johns Hopkins University19
撤回
3 期
Intron A for the Treatment of Hypertrophic ScarHypertrophic ScarBurnNCT00686478University of Alberta